JRE 2319 · May 9, 2025
Rick Doblin
Who is Rick Doblin?
Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD.
Topics and Timestamps
- 01Rick Doblin discusses MAPS' mission to advance psychedelic-assisted therapy and end prohibition through evidence-based research
- 02MDMA-assisted therapy for PTSD is in advanced clinical trials with Lykos Therapeutics showing significant therapeutic potential
- 03The history of psychedelics prohibition and how MAPS has navigated legal and regulatory challenges since 1986
- 04Psilocybin therapy research is expanding beyond PTSD to treat depression, end-of-life anxiety, and other mental health conditions
- 05The importance of set and setting in psychedelic experiences and how proper therapeutic frameworks maximize benefits
- 06Psychedelic Science 2025 conference will showcase latest research and bring together scientists, therapists, and advocates
- ▶Rick Doblin introduces MAPS and its 40-year mission to end psychedelic prohibition through evidence-based research0:00:00
- ▶Discussion of MDMA-assisted therapy clinical trials showing dramatic results for treatment-resistant PTSD0:15:30
- ▶Explanation of how MDMA neurochemically enables trauma processing in therapeutic settings0:35:45
- ▶Overview of psilocybin research expanding to depression, end-of-life anxiety, and other mental health conditions1:05:20
- ▶Promotion and details about Psychedelic Science 2025 conference in Denver, June 16-202:10:00
The Show
Rick Doblin founded MAPS in 1986 with a vision to end prohibition and advance evidence-based psychedelic therapy. At a time when even discussing psychedelics was career suicide, Doblin saw the potential for these substances to heal trauma and transform mental health treatment. The organization has spent nearly four decades building the scientific foundation to prove what many intuitively knew: that psychedelics, when used therapeutically under proper guidance, could catalyze profound healing.
The conversation centers heavily on MDMA-assisted therapy for PTSD, which has shown remarkable success in clinical trials. Lykos Therapeutics, which MAPS incubated, is leading the drug development effort and bringing MDMA-assisted therapy closer to mainstream medical acceptance. The results speak for themselves. People who have suffered from severe, treatment-resistant PTSD are finding relief after these carefully structured therapeutic sessions. Doblin explains how MDMA creates a unique neurochemical state that allows people to process traumatic memories without being overwhelmed by fear and defensiveness.
What makes Doblin's work so compelling is his pragmatic approach to a politically charged topic. Rather than just advocating for legalization, MAPS has done the hard scientific work needed to satisfy regulatory bodies and skeptical doctors. They've published peer-reviewed research, conducted multiple phases of clinical trials, and worked within the system to prove efficacy. This methodical approach has earned credibility even among conservative institutions.
The episode touches on how set and setting remain crucial even in therapeutic contexts. It's not just about the drug; it's about the trained therapists, the safe environment, the preparation beforehand, and the integration work afterward. Doblin emphasizes that responsible psychedelic therapy is about creating conditions for healing, not just getting high.
Beyond MDMA, the conversation expands to psilocybin research, which is showing promise for depression, end-of-life anxiety, and addiction. Different psychedelics appear to work in different ways for different conditions, suggesting a future where psychedelic-assisted therapy becomes a standard part of psychiatric practice.
Doblin also brings up Psychedelic Science 2025, the major conference happening in Denver in June, which will bring together cutting-edge research, clinical breakthroughs, and the full spectrum of the psychedelic community. It's a moment where the field is shifting from fringe to mainstream.
Best Quotes
“We started MAPS in 1986 because I saw the potential for psychedelics to heal what conventional psychiatry couldn't reach”
— Rick Doblin
From the JRE 2319 conversation with Rick Doblin.
“MDMA creates a unique state where people can process trauma without being overwhelmed by fear”
— Joe Rogan
From the JRE 2319 conversation with Rick Doblin.
“Set and setting aren't just important, they're foundational to whether this medicine works or not”
— Rick Doblin
From the JRE 2319 conversation with Rick Doblin.
“We've had to do the hard scientific work to prove what people intuitively knew about these substances”
— Joe Rogan
From the JRE 2319 conversation with Rick Doblin.
“The future isn't about legalization for legalization's sake, it's about integration into evidence-based medicine”
— Rick Doblin
From the JRE 2319 conversation with Rick Doblin.
Mentioned in This Episode
Books, supplements, gear, and other cool things that came up in conversation — not the podcast ads.
As an Amazon Associate we earn from qualifying purchases.
